Key points are not available for this paper at this time.
A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse. Chimeric antigen receptor T (CAR-T) cell therapy and bispecific antibodies are additional options.
S. Vincent Rajkumar (Fri,) studied this question.